研究论文开放获取

LB 02.3 Inno8, the first orally administered factor VIII mimetic shows favorable safety, pharmacokinetic, and pharmacodynamic properties in healthy male participants

Linda Ingemann, Andrea Navarria, Dorthe Gybel Vej Andersen, Henrik Mikael Schyllert, Mads Kreilgaard, Christian Keicher

Novo Nordisk (Denmark)　Novo Nordisk (Switzerland)

来源Research and Practice in Thrombosis and Haemostasis

年份2026

DOI10.1016/j.rpth.2026.106809

原文https://doi.org/10.1016/j.rpth.2026.106809

阅读操作

确认中

在文库中上传 PDF 后可生成中文音频讲解。

摘要与影响

摘要 · 完整

Inno8 is a bispecific heavy-chain-only antibody fragment that mimics activated factor VIII and is being developed as an oral prophylaxis for hemophilia A. To enable oral bioavailability, Inno8 is formulated as a tablet with salcaprozate sodium (SNAC), an absorption enhancer that facilitates gastric epithelial uptake.

逐年被引趋势

暂无年度引用数据

关键指标

被引次数 · OpenAlex

0.00

领域内被引倍数
同类平均 = 1

前 24%

引用位次
同领域 · 同年份 · 同类型

参考文献

Google Scholar 与 OpenAlex 的被引统计范围不同，数值存在差异属正常。

AI 辅助阅读

依据：摘要

论文问答

当前基于摘要回答

可就本文提问；依据不足时会说明。

学术脉络

学科主题

生物医学

Hemophilia Treatment and Research

Platelet Disorders and Treatments · Coagulation, Bradykinin, Polyphosphates, and Angioedema

参考文献 0

暂无参考文献明细

引用本文 -

暂无引用本文的记录